Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trialRaphael J. Landovitz, Joseph J. Eron, Paul Richardson et al.|PLoS Medicine|2018Cited by 171
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trialRaphael J. Landovitz, Craig W. Hendrix, Sue Li et al.|The Lancet HIV|2020Cited by 171
Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083Mark A. Marzinke, Susan H. Eshleman, Beatriz Grinsztejn et al.|The Journal of Infectious Diseases|2021Cited by 129
The promise and pitfalls of long-acting injectable agents for HIV preventionRaphael J. Landovitz, Marybeth McCauley, Ryan Kofron|Current Opinion in HIV and AIDS|2015Cited by 111
Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077Elizabeth E. Tolley, Raphael J. Landovitz, Sahar Z. Zangeneh et al.|AIDS and Behavior|2020Cited by 92